A new funding call is now open, with up to £700,000 per project available for innovators advancing target validation for novel mental health drug discovery. Wellcome launched the programme in collaboration with Medicines Discovery Catapult’s Psychiatry Consortium to help enable early and robust target validation research. The call will provide funding for validation activities for novel targets with a clear therapeutic concept and strong biological rationale related to early intervention in anxiety, depression and/or psychosis.